Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Ed Ajootian who wrote (1322)	10/26/1998 12:06:00 AM
From: M. Ramle	Read Replies (1) \| Respond to of 10280

Ed: Many thanks for all your info. regarding the Broker's meeting. Very encouraging indeed to add to one's position without looking back. Good Luck. Mazen

To: Ed Ajootian who wrote (1322)	10/26/1998 7:56:00 AM
From: BMcV	Read Replies (1) \| Respond to of 10280

Thanks Ed, Lots of good news in your report, (Claritin DCL a year ahead, coherent antihistamine strategy). I really like this though: "Southwell thinks Nori can be a billion $$ drug by '03. This would mean $250 mm gross margin to SEPR (assuming a 50% GM %). That's about $7 per fully-diluted share, for the mathematically challenged. Southwell thinks the analysts are undervaluing SEPR since they are only going out to '02 in their models and then discounting back ---- whereas the real fireworks aren't until '03." Picture the VL reports in 2001-3, when SEPR's earnings are doubling every year, what kind of multiple will the stock have then? And guess what -- that's not that far away!